- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Lighthouse Point Today
By the People, for the People
ZyVersa Therapeutics Reports Full Year 2025 Financial Results
Biopharmaceutical company provides business update on pipeline development
Mar. 31, 2026 at 9:50pm
Got story updates? Submit your updates here. ›
ZyVersa Therapeutics, a clinical-stage specialty biopharmaceutical company, has reported its financial results for the full year ending December 31, 2025, and provided a business update. The company is advancing a highly differentiated pipeline focused on inflammatory and renal diseases, with two lead programs - Inflammasome ASC Inhibitor IC 100 and Cholesterol Efflux Mediator VAR 200.
Why it matters
ZyVersa's pipeline targets inflammatory and renal diseases with a total accessible market over $100 billion. The company's lead programs have the potential to provide new treatment options for patients with significant unmet medical needs in these disease areas.
The details
ZyVersa is nearing completion of its preclinical program for Inflammasome ASC Inhibitor IC 100 and plans to file an IND in Q4-2026, followed by initiating a Phase 1 trial in overweight healthy subjects at risk of cardiometabolic conditions. The company also plans to initiate a preclinical study in Q2-2026 to support potential indication expansion of IC 100 in an orphan renal disease animal model. For Cholesterol Efflux Mediator VAR 200, ZyVersa has a clinical research organization in place to initiate a Phase 2a trial in patients with FSGS and Alport Syndrome in Q2-2026, with an interim read-out planned around Q4-2026.
- ZyVersa plans to file an IND for Inflammasome ASC Inhibitor IC 100 in Q4-2026.
- ZyVersa plans to initiate a Phase 1 trial for IC 100 in overweight healthy subjects at risk of cardiometabolic conditions in Q1-2027.
- ZyVersa plans to initiate a preclinical study for IC 100 in a diet-induced obesity mouse model in Q2-2026, with a preliminary read-out around Q3-2026.
- ZyVersa plans to initiate a preclinical study for IC 100 in an orphan renal disease animal model in Q2-2026, with a preliminary read-out around Q3-2026.
- ZyVersa plans to initiate a Phase 2a trial for Cholesterol Efflux Mediator VAR 200 in patients with FSGS and Alport Syndrome in Q2-2026, with an interim read-out planned around Q4-2026.
The players
ZyVersa Therapeutics, Inc.
A clinical-stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of inflammatory and renal diseases with high unmet medical needs.
Stephen C. Glover
ZyVersa's Co-founder, Chairman, CEO, and President.
What they’re saying
“The next 18 months are poised to be transformative for ZyVersa.”
— Stephen C. Glover, ZyVersa's Co-founder, Chairman, CEO, and President
What’s next
The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.
The takeaway
ZyVersa's pipeline of innovative therapies targeting inflammatory and renal diseases represents a significant opportunity, as the company advances its lead programs through key development milestones over the next 18 months.
